Tri Locum Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tri Locum Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30M	Buy	+158,663	New	+$27.7M	4.21%	12
2025 Q1	–	Sell	-161,812	Closed	-$19.9M	–	29
2024 Q4	$19.9M	Buy	+161,812	New	+$19.1M	4.13%	11
2022 Q4	–	Sell	-106,528	Closed	-$14.2M	–	84
2022 Q3	$14.2M	Buy	106,528 +49,165	+86%	+$7.48M	3.9%	8
2022 Q2	$8.95M	Sell	57,363 -73,315	-56%	-$11.3M	3.66%	11
2022 Q1	$20.3M	Buy	+130,678	New	+$19M	7.95%	1
2021 Q3	–	Sell	-89,370	Closed	-$15.9M	–	36
2021 Q2	$15.9M	Sell	89,370 -21,012	-19%	-$3.64M	5.2%	6
2021 Q1	$18.1M	Buy	+110,382	New	+$18.2M	4.5%	10

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Tri Locum Partners's JAZZ Position: Q1 2026 in Review

Tri Locum Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 158,663 shares worth $30M. The stake represents 4.21% of the portfolio and ranks #12 among its holdings. This is a return to the name: Tri Locum Partners previously reported a position in JAZZ as recently as Q4 2024.

Tri Locum Partners first reported a position in JAZZ in Q1 2021 and has held it in 7 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Tri Locum Partners held 158,663 shares of Jazz Pharmaceuticals worth $30M as of Q1 2026.
Jazz Pharmaceuticals was a new Tri Locum Partners position in Q1 2026.
Jazz Pharmaceuticals made up 4.21% of Tri Locum Partners's portfolio in Q1 2026, its #12 holding.
Tri Locum Partners first reported a position in Jazz Pharmaceuticals in Q1 2021 and has held it in 7 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.